ClinicalTrials.gg
RecruitingNCT06366724LIFTUpdated Oct 15, 2026

LIFT: Life Improvement Trial

A Phase 2 interventional study of Pyridostigmine and Low-Dose Naltrexone in ME/CFS, Long COVID and PASC, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Oct 15, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 86 studies in Fatigue Syndrome, Chronic with a site in United States — 21 open to participants now, 24 under way, none of them phase 3. Fatigue Syndrome, Chronic · United States.

Planned enrollment
8th of 58
160 · median 50
Started
2024
with 3 others
Phase 2
12 of 86
4 open now
Primary completion
2027-09
later than 16 of 23 live
Registered
74th of 86
by date
Lead sponsor
2 of 86
Brigham and Women's Hospital

Among the 86 studies in Fatigue Syndrome, Chronic with a site in United States, this one is the 8th largest by planned enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2024, is one of 12 in phase 2, reaches primary completion later than 16 of the 23 other live ones, and was the 74th registered.

Fatigue Syndrome, Chronic

265 studies on the registry are indexed under Fatigue Syndrome, Chronic; 63 are open to participants now.

Browse Fatigue Syndrome, Chronic studies →

Open to participants now

21 of the 86 studies in Fatigue Syndrome, Chronic with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Fatigue Syndrome, Chronic studies recruiting now, 19 (42%) set no upper age limit and 20 (44%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Fatigue Syndrome, Chronic with a site in United States, or all of them as a file.
02

Study summary

The LIFT will be conducted at Brigham and Women's Hospital (BWH) of Harvard Medical School, focusing on the effect of Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) in subjects aged 18-70 meeting the Canadian consensus criteria (CCC) for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) as well as having specifically Orthostatic Intolerance (OI). Long COVID (LC) subjects will also be included if they meet CCC and have OI.

This double-blind, placebo-controlled study will involve 160 participants randomized into one of four possible groups: Pyridostigmine/LDN (40), Pyridostigmine/Placebo (40), LDN/Placebo (40), Placebo/Placebo (40). The dose of Pyridostigmine will be carefully titrated from 30mg to 60mg three times a day, and the dose of LDN will be titrated from 1.5 mg to 4.5 mg once daily.

The trial includes a scale-back plan, allowing participants to reduce their dosage if they experience intolerance symptoms, with adjustments made during weekly visits. This plan provides a personalized approach to medication tolerance, ensuring participant's safety and comfort throughout the trial.

The time commitment for the participant is approximately three (3) months, and during this time, there will be three (3) in-person visits to BWH and four (4) virtual visits. Study procedures will include two (2) submaximum cardiopulmonary exercise tests, questionnaires (virtually completed), and blood and urine collection. We will be recruiting from the BWH Dyspnea Clinic as well as the Open Medicine Foundation (OMF) StudyME Registry and anticipate the entire trial will take two (2) years to complete.

The LIFT represents a significant endeavor to improve treatment options for ME/CFS patients and contribute to the broader understanding of this debilitating condition.

03

Conditions studied

  • ME/CFS
  • Long COVID
  • PASC

Keywords

  • Chronic fatigue
  • Mestinon
  • Low Dose Naltrexone
  • Orthostatic Intolerance
  • Post exertional malaise
  • Cognitive Impairment
  • Long COVID
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet National Academy of Medicine Criteria, Canadian Consensus Criteria (See appendix), and demonstrate orthostatic intolerance for diagnosis of ME/CFS
  2. Participant is ≥ 18 and ≤ 70 years of age at screening, inclusive.
  3. The onset of symptoms prior to December 2023.
  4. Female participant is not pregnant and at least 1 of the following conditions apply:

    1. Not a woman of
    2. Woman of childbearing potential who agrees to follow the guidance. from the time of .
  5. Participant agrees and can adhere to the study requirements for the length of the study.
  6. Participant has a (BMI) range of 17 to 40 kg/m2, inclusive.
  7. Participant agrees not to participate in another interventional study while participating in the present study.
  8. Participant has a functioning smart phone to download and run the DANA Brain Vital Mobile Application.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant, planning to become pregnant, or breastfeeding.
  2. Any use of opioid medications within 30 days of screening.
  3. Positive urine test for opioids
  4. History of alcohol, opioid or other substance misuse
  5. Participation in another interventional clinical trial in the last 30 days or planned during the trial period.
  6. Allergy to medication components
  7. Participant has any condition which, in the investigator's opinion, makes the participant unsuitable for study participation.
  8. Participant has diabetes mellitus (type 1 or 2).
  9. Participant has undergone an inpatient hospitalization within the 30 days prior to the randomization or has a planned hospitalization or a surgical procedure during the study, which may affect the study assessments, in the opinion of the investigator.
  10. Participant has respiratory disease (such as , cystic fibrosis, severe asthma, lung infections including tuberculosis, sarcoidosis, thoracic endometriosis, pulmonary fibrosis, and lung cancers) and/or cardiac disease (medical history or current clinical findings)
  11. Participant has an active or any other cancer.
  12. Participant has initiated an exercise regimen within 4 weeks prior to randomization.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    Pyridostigmine/LDN

    Pyridostigmine will be taken as liquid suspension three times a day, scaling up from 20mg (1.67mL) to 60mg (5mL) (180mg/day). Low dose naltrexone will be taken as liquid suspension once a day, scaling up from 1.5mL to 4.5mL (4.5mg/day).

    Drug: Pyridostigmine · Drug: Low-Dose Naltrexone

  • Active comparator
    Pyridostigmine/Placebo

    Pyridostigmine will be taken as liquid suspension three times a day, scaling up from 20mg (1.67mL) to 60mg (5mL) (180mg/day). Placebo will be taken as liquid suspension once a day, scaling up from 1.5mL to 4.5mL.

    Drug: Pyridostigmine · Other: Placebo

  • Active comparator
    Placebo/LDN

    Placebo will be taken as liquid suspension three times a day, scaling up from 1.67mL to 5mL. Low dose naltrexone will be taken as liquid suspension once a day, scaling up from 1.5mL to 4.5mL (4.5mg/day).

    Drug: Low-Dose Naltrexone · Other: Placebo

  • Placebo comparator
    Placebo/Placebo

    Placebo will be taken as liquid suspension three times a day, scaling up from 1.67mL to 5mL. Placebo will be taken as liquid suspension once a day, scaling up from 1.5mL to 4.5mL .

    Other: Placebo

Interventions

  • Pyridostigmine timeline: Weeks 0-2: 20mg TID (1.67 mL TID) Weeks 2-4: 40mg TID (3.33 mL TID) Weeks 5-13: 60mg TID (5mL TID)

    Also known as: Mestinon

  • DrugNaltrexoneStudies of NaltrexoneNaltrexone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    LDN timeline: Weeks 0-2: 1.5mg QD (1.5mL QD) Weeks 2-4: 3.0mg QD (3.0mL QD) Weeks 5-13: 4.5mg QD (4.5mL QD)

    Also known as: LDN

  • OtherPlacebo

    Placebo timeline: Weeks 0-2: 20mg TID (1.67mL TID)/1.5mg QD (1.5mL QD) Weeks 2-4: 40mg TID (3.33mL TID)/3.0mg QD (3.0mL QD) Weeks 5-13: 60mg TID (5mL TID)/4.5mg QD (4.5mL QD)

06

What researchers measure

Primary outcomes

  1. Functional Capacity

    Change in the total FUNCAP55 questionnaire score The FUNCAP55 is a questionnaire developed to assess the functional capacity of patients. Each question is answered on a 6-point scale. The greater the score, the better the functioning.

    Time frame: 15 weeks

  2. Physiologic Response - Oxygen Uptake Efficiency Slope (OUES)

    Changes in % of predicted oxygen uptake efficiency slope (OUES) between baseline and follow-up measured during a non-invasive cardiopulmonary exercise test (CPET)

    Time frame: 13 weeks

  3. Physiologic Response - Oxygen Utilization (VO2)

    Changes in % of predicted extrapolated peak oxygen utilization (extrapolated max VO2) between baseline and follow-up measured during a submaximum CPET

    Time frame: 13 weeks

  4. Physiologic Response - Heart Rate Recovery (HRR)

    Changes in 1-min heart rate recovery (HRR) in beats per minute (bpm) between baseline and follow-up measured during a submaximum CPET

    Time frame: 13 weeks

Secondary outcomes

  1. Post-Exertional Malaise

    Change in DePaul Symptom Questionnaire-1 (DSQ1) score The questionnaire lists 5 symptoms that are scored based on frequency and severity. Each question is answered on a 4-point scale. The greater the score, the greater the frequency and severity of the symptom.

    Time frame: 15 weeks

  2. PROMIS-29-Pain

    Change in PROMIS-29 questionnaire score Reflected as combination of the "pain interference" (0 to 5) and "pain intensity" (0 to 10) sections of the questionnaire will be secondary outcomes. The greater the score, the greater the pain experienced.

    Time frame: 15 weeks

  3. Daily Activity

    Change in daily steps (steps/day) measured using Garmin Vivosmart 5

    Time frame: 15 weeks

  4. Heart Rate Variability

    Change in heart rate variability (HRV) defined as the specific change in time (ms) between successive heart beats. All collected via Garmin VivoSmart5

    Time frame: 15 weeks

  5. Blood Oxygen

    Change in blood oxygen saturation (%) measured with Garmin VivoSmart 5

    Time frame: 15 weeks

  6. Resting Heart Rate

    Change in resting heart rate (bpm) using Garmin VivoSmart 5

    Time frame: 15 weeks

  7. DANA Brain Vital-Simple Reaction Time (SRT)

    Change in time (ms) required to recognize the presence of an object and tap the object

    Time frame: 15 Weeks

  8. DANA Brain Vital-Procedural Reaction Time (PRT)

    Change in time (ms) required to recognize 1 of 4 numbers and tap 1 of 2 buttons

    Time frame: 15 weeks

  9. DANA Brain Vital-Memory Search (MS)

    Change in time (ms) required to recognize letters that have previously been memorized

    Time frame: 15 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after de-identification(text, tables, figures, and appendices) will be available for researchers who provide a methodologically sound proposal to achieve aims in the approved proposal.

Supporting information: Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Beginning 9 months and ending 36 months following article publication.

Access criteria: Proposals should be directed to jsquires1@bwh.harvard.edu. To gain access, data requestors will need to sign a data access agreement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Sep 2026 → Sep 2027 and completion Nov 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2024
First posted
Apr 16, 2024
StartActual
Sep 10, 2024
Primary completionEst.
Sep 2027was Sep 2026
CompletionEst.
Dec 2027was Nov 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Sep 2027
Oct 15, 2026
Study completion
Nov 2026→Dec 2027
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion Sep 2026→Sep 2027
    Study completion Nov 2026→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06366724
Collaborators
Open Medicine Foundation
Responsible party
David Systrom (Principal Investigator; Director, Dyspnea Center; Associate Professor of Medicine, Brigham and Women's Hospital) — Principal investigator
First posted
Apr 16, 2024
Start date
Sep 10, 2024
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Research Coordinator
Contact
jsquires1@bwh.harvard.edu
617-525-6797
David Systrom, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pyridostigmine · Naltrexone

Start the discussion